Before we dig into improved delivery methods, we need to acknowledge a more basic issue: women need more therapeutics in the first place. Persistent gaps exist across conditions that uniquely or disproportionally affect women. Gynecologic infections, endometriosis, the vaginal microbiome. Menopause, contraception, oncology.
As the biocatalytic toolbox expands, chemists have gained access to a wider range of catalytic options, enabling improved stereo- and regioselectivity, simplified chemical synthesis routes, improved process mass intensity (PMI), reduced environmental impact and stronger process economics.
In this talk, Micah Tuttle demonstrates how intentional, forward-looking drug product design from day one can dramatically accelerate clinical development—eliminating the need for costly, time-consuming reformulations and bridging studies.
Shaukat Ali, PhD, and Jim Huang, PhD, review a few examples of controlled release excipients and their attributes from monolithic matrix tablets and polymeric coated tablets.
True Rogers, RPh, PhD, Matthias Knarr, PhD, and Mark Dreibelbis, PhD, say excipient selection is a key consideration within the QbD framework, particularly for CR technologies. Excipients must be chosen carefully to ensure they deliver the needed processability, quality, stability, and performance during and following the manufacture of dosage forms.
Nandkumar Deorkar, PhD, explores some of the key challenges in mAb formulation and fill-finish, offering practical insights to help developers navigate complexity and ensure success.
Mary Schuster introduces a new approach to perfecting oral suspension formulations, which is centered on the strategic use of a “novel” synthetic functional excipient, magnesium aluminometasilicate (MAS).
COMPANY PROFILE
Genizer LLC is headquartered in Irvine, CA, with an East Coast presence just outside Boston, MA, and we’ve been in business nearly 15 years. Our mission is to advance nanotechnology. Our world renowned DIAMOND INTERACTION CHAMBERS are made solely by Genizer LLC; they are compatible with most other brands of high pressure homogenizers and high pressure pumps. These chambers give you best quality, the same processing results /efficiencies as other brands, at a fraction of the cost. Click here for
Why Early Development Requires a Different Decision Model
Early oral drug development is an exercise in working under constraint. Teams are asked to make consequential decisions when materials are limited, timelines are tight, and the data are incomplete. Traditionally, formulation …
The white paper, Small Molecules: Choosing the Right Development Path, outlines a structured, risk-minimized approach to early CMC (Chemistry, Manufacturing, and Controls) development for small-molecule drugs—particularly for startups and virtual pharma companies with limited resources.
By: Harry Wade, Technical Associate, and Rosie Bird, EHS Lead, Catalent Dartford
The pharmaceutical industry faces a growing manufacturing challenge as therapeutic compounds become increasingly potent and targeted. Oncology and hormonal APIs, often designed for ultra-low dosing, promise meaningful clinical …
DRUG DEVELOPMENT DIRECT RESOURCES
Upcoming eNewsletter Features:
April 1 – Inhalation Delivery
April 8 – Formulation Development